Abbott Laboratories: There May Be A Surge Coming Next Week (Earnings Preview)

Abbott Laboratories (ABT) is set to report Q3 earnings next week, with analysts anticipating an EPS of $1.30, marking an 8.3% year-over-year increase. The stock previously declined by nearly 9% following Q2 results, attributed to expectations of a larger beat, despite strong earnings. Strategically, Abbott is expanding its presence in the diabetes ecosystem through data-driven solutions, and its current P/E of 16.8x suggests potential undervaluation compared to historical and sector averages, though high competition in core growth areas poses a key risk.

Analysis

Abbott Laboratories (NYSE:ABT) is expected to report its Q3 earnings on Wednesday next week. Back when the company released its previous results, FY25'Q2, on the 17th of July, ABT stock dropped almost 9%, from $131 to $120. This selloff had come Abbott Laboratories: There May Be A Surge Coming Next Week (Earnings Preview) Summary - Abbott Laboratories is set to report Q3 earnings, with EPS expectations of $1.30, reflecting 8.3% YoY growth. - Abbott’s Q2 results showed strong earnings growth, but the stock fell due to expectations of a bigger beat. - The company is building a defensible position in the diabetes ecosystem, moving beyond devices to data-driven, integrated care solutions. - Abbott trades at a P/E of 16.8x, well below its historical average and the healthcare sector median, suggesting undervaluation. - The key risk is high competition in its core growth areas, but successful execution could yield outsized long-term shareholder returns. Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body. Abbott Laboratories (ABT) is slated to report its Q3 earnings next week, with current analyst expectations set at an EPS of $1.30, reflecting an 8.3% year-over-year growth. The stock previously experienced a notable 9% decline, from $131 to $120, following its Q2 earnings release on July 17th, a reaction attributed to market expectations for a larger earnings beat despite strong reported results. This prior market response indicates a sensitive investor base with high performance benchmarks. The company is actively strengthening its market position within the diabetes ecosystem, strategically shifting from traditional device offerings to more comprehensive, data-driven, and integrated care solutions. This strategic pivot aims to build a defensible competitive advantage and foster long-term growth. ABT's current valuation, with a P/E multiple of 16.8x, trades significantly below both its historical average and the median for the broader healthcare sector, suggesting a potential undervaluation. However, a key risk factor remains the high level of competition across its core growth areas. Despite competitive pressures, successful execution of its strategic initiatives, particularly in integrated care, could unlock substantial long-term shareholder value. The prevailing sentiment surrounding ABT is strongly positive and bullish, as indicated by a high per-ticker sentiment score of 0.8, reinforcing the optimistic outlook for its upcoming earnings.

Key Decisions for Investors

• Investors should closely monitor Abbott's Q3 earnings report, specifically focusing on revenue growth and forward guidance, given the market's previous reaction to expectations exceeding actual Q2 results.
• Evaluate the company's progress and strategic execution in its data-driven, integrated diabetes care solutions, as successful implementation in this segment is critical for realizing outsized long-term shareholder returns.
• Consider the current P/E valuation of 16.8x relative to historical averages and sector benchmarks, which may present a compelling entry point if the Q3 results provide fundamental validation and address competitive concerns.